Stoke Therapeutics Unveils Zorevunersen Breakthrough Data for Dravet Syndrome at AES 2024

Stoke Therapeutics Showcases Breakthrough Data on Zorevunersen at AES 2024 Annual Meeting

Stoke Therapeutics, Inc., a pioneering biotechnology firm in RNA medicine, prepares to unveil groundbreaking data on zorevunersen at the upcoming American Epilepsy Society (AES) 2024 Annual Meeting in Los Angeles, California. Scheduled from December 6-10, the conference serves as a platform for the company to present zorevunersen as a potential first disease-modifying treatment for Dravet syndrome, a severe and challenging form of epilepsy. Dr. Barry Ticho, the Chief Medical Officer of Stoke Therapeutics, emphasizes the significance of the findings which demonstrate the treatment's efficacy in patients already on optimal anti-seizure medications.

The data presented by Stoke includes results from a Phase 1/2 study involving nine patients, who received an initial dose of 70mg of zorevunersen, followed by a 45mg dose in an open-label extension. Notably, the research indicates sustained reductions in seizure frequency over a 24-month period, alongside substantial improvements in cognitive and behavioral outcomes as assessed by the Vineland-3 scale. The treatment is reported to be well-tolerated, marking a promising advancement in the management of Dravet syndrome. This data underscores Stoke's commitment to developing innovative therapies aimed at improving the quality of life for patients and their families.

In addition to the data presentation, Stoke Therapeutics will host a virtual event on December 9, featuring discussions led by prominent clinicians and patient advocates. This event aims to foster dialogue around the potential of zorevunersen to modify disease progression and enhance patient outcomes. Presentations during the AES meeting will also include insights from esteemed professionals affiliated with leading academic institutions, further solidifying zorevunersen's role in the evolving landscape of pediatric epilepsy treatment.

Stoke Therapeutics continues to position itself as a key player in the biotechnology sector, focusing on RNA-based therapies that address unmet medical needs. The ongoing research and data dissemination at the AES Annual Meeting reflect the company's dedication to advancing treatments that could significantly change the lives of children suffering from Dravet syndrome. As the meeting approaches, the anticipation surrounding zorevunersen builds, capturing the attention of healthcare professionals, researchers, and the families affected by this debilitating condition.